We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Vascular Occluder Targets Wide Range of Peripheral Arteries

By HospiMedica International staff writers
Posted on 30 Dec 2020
Print article
Image: The LOBO 3-disc braided occluder system (Photo courtesy of Okami Medical)
Image: The LOBO 3-disc braided occluder system (Photo courtesy of Okami Medical)
A new platform provides interventional physicians with “one-and-done” solution for the occlusion of a peripheral arterial targets.

The Okami Medical LOBO (LOw-profile Braided Occluder) system combines neurovascular-derived HDBRAID technology with a patented design so as to create a highly occlusive structure for fast and efficient closure of blood vessels throughout the body. HDBRAID allows braided devices to be made with wires less than 20 microns in diameter, about ¼ the thickness of a human hair. This results in over 5,000 pores, with four times greater pore density than conventional occluders, which significantly reduces flow and accelerates hemostasis and thrombosis.

Features include a dense pore structure for rapid occlusion of a wide range of vessels; microcatheter delivery with instantaneous mechanical detachment; excellent trackability, even in small, tortuous vessels; conformance to curved vessels and expansion to accessible anatomical locations; retrievability prior to release; high stability following placement; and no spinnaker effect. The system includes the LOBO-5, intended for use in 3-5 mm diameter vessels, and the LOBO-3, intended for use in 1.5-3 mm vessels. It is not indicated for use in blood vessels where crush or bend forces are anticipated, such as joint areas and superficial vasculature.

“Guided by world-class physician collaborators, Okami is committed to addressing numerous challenging aspects of peripheral vascular occlusion,” said Bob Rosenbluth, PhD, president and CEO of Okami Medical. “LOBO-3 and LOBO-5, to be followed by LOBO-7 and LOBO-9, are designed and built to enable fast, predictable and complete occlusion of a diverse set of vascular targets, without the need for multiple embolic devices.”

Peripheral vascular occlusion is intended for the treatment of hemorrhages, aneurysms, and tumor isolation, including nephroma, hematoma, and other vascular malformations, and uterine fibroids, among other conditions.

Related Links:
Okami Medical


Print article

Channels

Business

view channel
Illustration

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.